Ehab El-Gabry - 19 May 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Chief Medical Officer
Signature
/s/ Ehab El-Gabry, by Brian McKelligon, as Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
19 May 2022
Net transactions value
$0
Form type
4
Filing time
23 May 2022, 18:15:16 UTC
Previous filing
19 Apr 2022
Next filing
27 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 19 May 2022 Common Stock 150,000 $9.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the reporting person's continuing service, the options shall vest as follows: twenty-five percent (25%) shall have vested on April 11, 2023 with the remainder vesting in 36 equal monthly installments beginning on April 11, 2023.